EORTC 22042-26042

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase II and observation study.

Status as of 22 June 2009

On behalf of Damien Weber (SC) and the HQ team

EORTC 22042-26042: The team

- **Coordinating group:** EORTC ROG
  Study Coordinator: D. Weber (Geneva, Switzerland)
- **Cooperative group:** EORTC BTG

- **EORTC team:**
  - Clinical Research Physician: Cecilia Liberatoscioli
  - Project manager: Nadège Gosselin
  - Data Manager: Sarah Morren
  - QA RT manager: Akos Gulyban
  - Regulatory Affairs Officer: Marta Marques
  - Statistician: Laurence Collette
  - Clinical Trial Assistant: Aurélia Siraut

EORTC 22042-26042: Study Design



EORTC 22042-26042: Eligibility

Main eligibility criteria:

- Patients with WHO grade-II or grade-III meningioma
- Complete or subtotal resection (any Simpson stage)
- Age > 18 and < 70 yr
- PS WHO 0-2

EORTC 22042-26042: Endpoints

Primary endpoint and objective:

- **Progression free survival at 3 years**
- **Aim: demonstrate that 3-year progression free survival < 70% for patients with Simpson's stage 1-3 and < to 50% for patients with Simpson's stage 4-5.**

Secondary endpoints:

- **Overall survival**
- **Toxicity**
- **Mini mental status**

EORTC 22042-26042: Participating Sites

European Union Countries: 6

(active / in progress)

Austria: - / 1

Belgium: 1 / 1

France: 3 / 4

Germany: 1 / 1

Italy: 2 / 2

Spain: 2 / 2

The Netherlands: 5 / 5

United Kingdom: 2 / 4



Non-EU Countries: 2

Switzerland: 1 / 1

Turkey: 1 / 1

9 Countries activated out of 10 participating countries

18 sites activated out of 22 participating Sites

EORTC 22042-26042:
Expected Accrual vs. Current Accrual

12 patients registered
(25 expected patients at 22/03/2009)